Claudin 18.2 (CLDN18.2) expression prevalence, prognostication and clinical variables in gastric and gastroesophageal junction adenocarcinoma patient samples

被引：0
|
作者：
Sewastjanow, Matheus
Yamashita, Kohei
Iwata, Kenneth K.
Moran, Diarmuid
Elsouda, Dina
Pizzi, Melissa
Vicentini, Ernesto Rosa
Shanbhag, Namita
Ta, Anh
Waters, Rebecca
Chatterjee, Deyali
Ajani, Jaffer
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-2141
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2141
引用
收藏
页数：3
相关论文
共 50 条
  • [11] Prognostic value of claudin 18.2 expression in gastric adenocarcinoma
    Kayikcioglu, Erkan
    Yuceer, Ramazan Oguz
    Cetin, Bulent
    Yuceer, Kamuran
    Karahan, Nermin
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 15 (02) : 343 - 351
  • [12] CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer
    Canming Wang
    Yukai Wang
    Jinxia Chen
    Yi Wang
    Chuhong Pang
    Chen Liang
    Li Yuan
    Yubo Ma
    BMC Gastroenterology, 23
  • [13] Prognostic value of claudin 18.2 expression in gastric adenocarcinoma
    Erkan Kayikcioglu
    Ramazan O?uz Yüceer
    Bulent Cetin
    Kamuran Yüceer
    Nermin Karahan
    World Journal of Gastrointestinal Oncology, 2023, 15 (02) : 343 - 351
  • [14] Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer
    Kubota, Yohei
    Shitara, Kohei
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [15] Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+gastric or gastroesophageal junction adenocarcinoma
    Shitara, Kohei
    Kawazoe, Akihito
    Hirakawa, Akihiro
    Nakanishi, Yuka
    Furuki, Satomi
    Fukuda, Musashi
    Ueno, Yoko
    Raizer, Jeffrey
    Arozullah, Ahsan
    CANCER SCIENCE, 2023, 114 (04) : 1606 - 1615
  • [16] CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer
    Wang, Canming
    Wang, Yukai
    Chen, Jinxia
    Wang, Yi
    Pang, Chuhong
    Liang, Chen
    Yuan, Li
    Ma, Yubo
    BMC GASTROENTEROLOGY, 2023, 23 (01)
  • [17] Expression and prognostic analysis of CLDN18 and Claudin18.2 in lung adenocarcinoma
    Liu, Junying
    Yang, Huichai
    Yin, Danjing
    Jia, Ying
    Li, Shi
    Liu, Yueping
    PATHOLOGY RESEARCH AND PRACTICE, 2022, 238
  • [18] CLDN18.2 expression in resectable gastroesophageal cancers: Associated clinical and molecular signatures and impact of neoadjuvant chemotherapy on intratumor heterogeneity
    Cammarota, A.
    Devonshire, G.
    Miremadi, A.
    Zhuang, L.
    Zamani, S.
    Smith, R.
    Masque-Soler, N.
    Ustaoglu, A.
    Rimassa, L.
    Fitzgerald, R.
    Smyth, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S166 - S167
  • [19] SYMPTOM BURDEN AND HEALTHCARE RESOURCE USE IN CLAUDIN 18.2+(CLDN18.2+), HER2-PATIENTS WITH LOCALLY ADVANCED (LA) UNRESECTABLE OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION (MG/GEJ) ADENOCARCINOMA
    Sewastjanow-Silva, M.
    Rogers, J. E.
    Waters, R. E.
    Rosa, Vicentini E.
    Totev, T.
    Wu, Eq
    Yang, H.
    Chang, L.
    Oh, M.
    Ajani, J.
    VALUE IN HEALTH, 2024, 27 (06) : S401 - S401
  • [20] Development and comparison of three 89Zr-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer: a preclinical study
    Hu, Guilan
    Zhu, Wenjia
    Liu, Yu
    Wang, Yuan
    Zhang, Zheng
    Zhu, Shikun
    Duan, Wenwen
    Zhou, Peipei
    Fu, Chao
    Li, Fang
    Huo, Li
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (08) : 2634 - 2644
12345